Factor Xa

Cat. No.

A74715

CAS No.

183305-24-0

Fidexaban

Fidexaban is a potent Factor Xa inhibitor that plays a significant role in the modulation of the coagulation cascade. It is primarily utilized in cardiovascular disease research, providing valuable insights into thrombotic disorders and potential therapeutic strategies. Its mechanism of action contributes to the understanding of anticoagulant therapies and their implications in various pathological conditions.

Cat. No.

A74718

CAS No.

1378266-98-8

Zifaxaban

Zifaxaban is a selective and competitively acting Factor Xa (FXa) inhibitor, demonstrating an IC50 of 11.1 nM for human FXa. This compound exhibits over 10,000-fold selectivity against other serine proteases. It serves as a valuable tool for research on arterial and venous thrombosis, facilitating investigations into antithrombotic therapies and mechanisms of coagulation.

Cat. No.

A74720

CAS No.

2099719-47-6

Betrixaban hydrochloride

Synonyms: PRT054021 hydrochloride

Betrixaban hydrochloride is a highly potent and selective inhibitor of factor Xa (fXa), exhibiting an IC50 of 1.5 nM. This compound demonstrates significant antithrombotic activity, making it valuable for research applications focused on thrombosis and coagulation disorders. Betrixaban hydrochloride is suitable for studies investigating novel anticoagulant therapies and the mechanistic pathways of blood clotting.

Cat. No.

A74721

CAS No.

480448-29-1

Edoxaban hydrochloride

Synonyms: DU-176 hydrochloride

Edoxaban hydrochloride is a highly selective, direct Factor Xa (FXa) inhibitor. With Ki values of 0.561 nM and 2.98 nM for free human FXa and prothrombinase, respectively, it exhibits over 10,000-fold selectivity against other coagulation proteases. This compound is primarily utilized in research applications related to the prevention of thromboembolic diseases, making it a valuable tool in cardiovascular and hematological studies.

Cat. No.

A74722

CAS No.

405940-76-3

Razaxaban hydrochloride

Synonyms: BMS 561389 hydrochloride; DPC 906 hydrochloride

Razaxaban hydrochloride is a selective and potent inhibitor of factor Xa, exhibiting a Ki of 0.19 nM. With over 5000-fold selectivity for factor Xa compared to other serine proteases, this compound effectively impedes the coagulation cascade. Additionally, Razaxaban hydrochloride displays thrombin inhibition with a Ki value of 540 nM, underscoring its significant antithrombotic properties. It is a valuable tool for research into anticoagulation therapies and the modulation of thrombotic disorders.

Cat. No.

A74724

CAS No.

811811-33-3

EMD 495235

EMD 495235 is a potent and orally active inhibitor of coagulation factor Xa, exhibiting an IC50 of 5.5 nM and a Ki of 6.8 nM. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and hemostasis. EMD 495235 can be utilized to investigate the mechanisms of coagulation and evaluate potential therapeutic strategies for related disorders.

Cat. No.

A74730

CAS No.

155204-81-2

DX-9065a

DX-9065a is a selective, nonpeptidic inhibitor of factor Xa (FXa), exhibiting a Ki of 41 nM for human FXa. This compound demonstrates potent anticoagulant properties while maintaining low activity against other serine proteases. Its specific targeting of FXa makes DX-9065a a valuable reagent in cardiovascular research and studies related to thrombosis.

Cat. No.

A74732

CAS No.

313489-71-3

LY-517717

LY-517717 is a potent and orally bioavailable inhibitor of Factor Xa (FXa). This compound exhibits significant antithrombotic and anticoagulant properties, making it valuable for research applications focused on venous thromboembolism, particularly in the context of hip or knee replacement surgeries. Its effectiveness in targeting FXa positions LY-517717 as a promising candidate for further investigations in thrombotic disorders.

Cat. No.

A74734

CAS No.

441328-10-5

FXa-IN-1

FXa-IN-1 is a potent factor Xa (FXa) inhibitor, exhibiting an IC50 of 3 nM and a Ki value of 0.7 nM. This compound demonstrates notable oral bioavailability and a favorable half-life in vivo, making it effective for research in thromboembolic disorders. FXa-IN-1 is valuable for studying coagulation pathways and assessing therapeutic interventions in related diseases.

Cat. No.

A74736

CAS No.

768370-75-8

EMD-503982

EMD-503982 is an orally bioavailable inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By selectively inhibiting Factor Xa, this compound effectively reduces thrombin generation, making it a valuable tool in research focused on thrombosis and coagulation disorders. Its utility in various biological assays and preclinical studies further supports investigations into anticoagulant therapies and related cardiovascular research.

Cat. No.

A74737

CAS No.

150612-55-8

DX-9065a free base

DX-9065a free base is a selective nonpeptidic inhibitor targeting factor Xa (FXa), exhibiting a Ki of 41 nM for human FXa. With minimal activity against other serine proteases, this compound demonstrates robust anticoagulant properties. It is suited for research applications focused on coagulation pathways and the development of therapeutic agents for thromboembolic disorders.

Cat. No.

A74742

CAS No.

409081-12-5

Otamixaban hydrochloride

Synonyms: FXV673 hydrochloride

Otamixaban hydrochloride is a selective and reversible inhibitor of factor Xa (fXa), exhibiting a competitive mechanism with a Ki of 0.5 nM. It effectively inhibits both free and prothrombinase-bound fXa, providing a rapid action in thrombin generation management. This compound is primarily utilized in research exploring anticoagulation therapies and evaluating the biochemical pathways involved in coagulation disorders.

Cat. No.

A74743

CAS No.

1986-15-8

L-Guluronic acid

L-Guluronic acid is a coagulation Factor Xa inhibitor that retains the inhibitory activity against Factor Xa while serving as a substitute for L-Iduronic acid in anticoagulant pentasaccharides derived from heparin-like substances. Its capacity to modulate coagulation processes makes it valuable in research focused on coagulation disorders, including deep vein thrombosis and pulmonary embolism. This compound facilitates the exploration of therapeutic strategies aimed at managing these significant vascular conditions.

Cat. No.

A74748

CAS No.

205054-36-0

RPR 130737

RPR 130737 is a selective and potent competitive inhibitor of Factor Xa, exhibiting an inhibition constant (Ki) of 2.4 nM. This compound demonstrates over 1000-fold selectivity against thrombin, activated protein C, plasmin, tissue-plasminogen activator, and trypsin, making it an ideal tool for cardiovascular research. RPR 130737 effectively prolongs both activated partial thromboplastin time and prothrombin time while having no impact on platelet aggregation. It is primarily utilized in studies relating to thrombotic disorders and cardiovascular diseases.

Cat. No.

A74749

CAS No.

409358-98-1

KFA-1982

KFA-1982 is a potent and selective inhibitor of factor Xa, functioning as an anticoagulant in cardiovascular research. This orally active compound is valuable for investigating thrombotic disorders and related cardiovascular diseases. Its mechanism of action supports studies focused on the modulation of coagulation pathways and potential therapeutic interventions in thrombosis.

Cat. No.

A74750

CAS No.

209285-84-7

RPR-208707

RPR-208707 is a selective inhibitor of Factor Xa, exhibiting a Ki of 18 nM. This compound demonstrates significant anti-thrombotic activity, making it a valuable tool for research focused on thrombosis-related diseases. Its specificity for Factor Xa positions it as a potent candidate for exploring mechanisms of coagulation and potential therapeutic interventions in thrombotic disorders.

Cat. No.

A74751

CAS No.

1438492-27-3

Ciraparantag TFA

Synonyms: PER977 TFA

Ciraparantag TFA is a potent thrombin and factor Xa inhibitor utilized as a broad-spectrum reversal agent for anticoagulants. It effectively antagonizes the effects of various anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and specific direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. This compound is significant for research applications focused on enhancing hemostatic management in patients receiving anticoagulant therapy.

Cat. No.

A74753

CAS No.

209285-82-5

FXa-IN-3

FXa-IN-3 is a potent inhibitor of coagulation factor Xa (FXa), exhibiting a Ki of 43 nM. This small molecule demonstrates significant biological activity in the modulation of the coagulation cascade and is valuable for research related to thromboembolic diseases, including deep vein thrombosis and pulmonary embolism. Applications may include the study of anticoagulant mechanisms and the development of novel therapeutics targeting coagulation pathways.

Cat. No.

A74754

CAS No.

96440-64-1

Bacithrocin D

Synonyms: Thiolstatin D

Bacithrocin D is a potent inhibitor of key proteases, specifically targeting thrombin, factor Xa, trypsin, and papain. It effectively prolongs clotting time, making it valuable in studies related to coagulation and hemostasis. Bacithrocin D demonstrates IC50 values of 124 μM for thrombin, 9 μM for factor Xa, 0.85 μM for trypsin, and a remarkable 0.01 μM for papain, showcasing its high potency against these proteases. This reagent is useful for investigating protease-related pathways and developing therapeutic strategies in anticoagulation research.

Cat. No.

A74755

CAS No.

1255529-24-8

(1R,2R,4R)-Edoxaban

Synonyms: (1R,2R,4R)-DU-176

(1R,2R,4R)-Edoxaban is a selective inhibitor of activated coagulation factor X (Factor Xa). It demonstrates potent anticoagulant activity, making it a valuable tool in the study of thrombosis and related cardiovascular conditions. This reagent is suitable for researching mechanisms of coagulation and evaluating therapies aimed at managing thromboembolic disorders.

Cat. No.

A74758

CAS No.

1622159-00-5

BI-11634

BI-11634 is a potent factor Xa inhibitor that plays a critical role in anticoagulant research. It is primarily metabolized by the enzyme CYP3A4, leading to the formation of a major metabolite. The metabolism of BI-11634 can be inhibited by Quinidine, demonstrating a Ki value of 7 µM, indicating its potential importance in studies related to drug interactions and cardiovascular therapeutics.

Cat. No.

A74760

CAS No.

432029-12-4

Darexaban glucuronide

Synonyms: YM-222714

Darexaban glucuronide is an active metabolite of darexaban, functioning as a potent inhibitor of Factor Xa. This compound exhibits significant oral bioactivity and demonstrates antithrombotic effects, making it valuable for research into thromboembolic disorders. Its properties support studies focused on anticoagulant therapies and the mechanistic understanding of coagulation pathways.

Cat. No.

A74764

CAS No.

365462-61-9

AS1468240

AS1468240 is a potent, orally active inhibitor of factor Xa (fXa), demonstrating an IC50 of 8.7 nM against human fXa. This compound effectively prolongs coagulation time in murine models, highlighting its potential as an anticoagulant agent. It serves as a valuable tool for research into coagulation pathways and the development of therapeutic strategies for thromboembolic disorders.

Cat. No.

A74765

CAS No.

209187-02-0

YM-60828 methanesulfonate

YM-60828 methanesulfonate is a selective inhibitor of factor Xa (FXa) that exhibits significant antithrombotic properties. In preclinical studies using a rat arteriovenous shunt model, YM-60828 effectively reduces levels of thrombin-antithrombin III complex (TAT) in a dose-dependent manner without prolonging coagulation time. Its specific action on FXa, rather than thrombin, highlights its potential for therapeutic applications aimed at managing thrombotic disorders while allowing for TAT monitoring as a measure of its antithrombotic effect.

Cat. No.

A74767

CAS No.

1379458-40-8

FXa-IN-2

FXa-IN-2 is a reversible inhibitor of factor Xa (FXa), exhibiting an IC50 value of 45.08 μM. This compound is primarily utilized in the research of thromboembolic diseases, enabling scientists to explore the modulation of coagulation pathways and potential therapeutic interventions. Its effectiveness as an FXa inhibitor makes it valuable for studies focused on anticoagulation mechanisms and treatment strategies.